MG
CUE icon

Mather Group’s Cue Biopharma CUE Stock Holding History

Mather Group’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.04K Hold
33
– – ﹤0.01% 1797
2026
Q1 		$230 Buy
+33
New +$308 ﹤0.01% 1842
2025
Q4 		– Sell
-33
Closed -$719 – 868
2025
Q3 		$719 Buy
+33
New +$774 ﹤0.01% 1602
2025
Q2 		– Sell
-33
Closed -$911 – 858
2025
Q1 		$911 Buy
+33
New +$1.23K ﹤0.01% 1646

Other funds holding CUE

RSWM
Robertson Stephens Wealth Management San Francisco, California $4.06B AUM 32.22% 1-Year Est. Return
AWM
Angeles Wealth Management Santa Monica, California $2.19B AUM 23.13% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
GG
Gleason Group Prospect, Kentucky $1.15B AUM 21.11% 1-Year Est. Return
GSWM
Golden State Wealth Management Santa Ana, California $1.1B AUM 27.49% 1-Year Est. Return
PWA
Physician Wealth Advisors Midvale, Utah $837M AUM 26% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Mather Group's CUE Position: Q2 2026 in Review

Mather Group held its Cue Biopharma (CUE) position steady in Q2 2026 at 33 shares worth $1.04K. The position accounts for ﹤0.01% of the portfolio, ranked #1797.

Mather Group first reported a position in CUE in Q1 2025 and has held it in 4 quarters since. 8 funds tracked by Wall St. Rank hold CUE as of Q2 2026.

  • Mather Group held 33 shares of Cue Biopharma worth $1.04K as of Q2 2026.
  • Mather Group left its Cue Biopharma share count unchanged in Q2 2026.
  • Cue Biopharma made up ﹤0.01% of Mather Group's portfolio in Q2 2026, its #1797 holding.
  • Mather Group first reported a position in Cue Biopharma in Q1 2025 and has held it in 4 quarters since.
  • 8 funds tracked by Wall St. Rank held Cue Biopharma as of Q2 2026.

Based on Mather Group's 13F filing for Q2 2026, filed 27 Jul 2026.